Patent
Cephalosporin compounds
| العنوان: | Cephalosporin compounds |
|---|---|
| Patent Number: | 5,389,625 |
| تاريخ النشر: | February 14, 1995 |
| Appl. No: | 07/849,019 |
| Application Filed: | June 08, 1992 |
| مستخلص: | Cephalosporin compounds of the formula (I) ##STR1## wherein R.sup.1 is hydrogen atom or lower alkyl, and R.sup.2 is 1-alkanoyloxyalkyl or 1-alkoxycarbonyloxyalkyl, their pharmaceutically acceptable salts, methods for producing them, and pharmaceutical use thereof. The cephalosporin compounds and their salts are superior in absorption from digestive tract, and upon absorption from the digestive tract, show a wide range of antimicrobial activities in the body as hydrolysis products, and in addition, they have 10-400 times greater sweetness than sucrose. Thus, said compounds are useful as agents to be administered orally for the prophylaxis and treatment of bacterial infectious diseases. |
| Inventors: | Muro, Hiroyuki (Shiga, JPX); Kasai, Masayasu (Kyoto, JPX); Hatano, Satoru (Kameoka, JPX); Nishimura, Ken-ichi (Kyoto, JPX); Nishizawa, Susumu (Kyoto, JPX); Kakeya, Nobuharu (Nagaokakyo, JPX) |
| Assignees: | Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JPX) |
| Claim: | What is claimed is |
| Claim: | 1. A cephalosporin compound of the formula (I) ##STR16## wherein R.sup.1 is hydrogen atom or lower alkyl, and R.sup.2 is 1-alkanoyloxyalkyl or 1-alkoxycarbonyloxyalkyl except 1-cyclohexyloxycarbonyloxyethyl, or its pharmaceutically acceptable salt. |
| Claim: | 2. A cephalosporin compound according to claim 1, wherein R.sup.2 is selected from the group consisting of acetoxymethyl, propionyloxymethyl, n-butyryloxymethyl, isovaleryloxymethyl, pivaloyloxymethyl, 1-acetoxyethyl, 1-propionyloxyethyl, 1-isobutyryloxyethyl, 1-n-valeryloxyethyl, 1-isovaleryloxyethyl, 1-pivaloyloxyethyl, 1-ethoxycarbonyloxethyl, and 1-isopropoxycarbonyloxyethyl, or its pharmaceutically acceptable salt. |
| Claim: | 3. A cephalosporin compound according to claim 1 which is selected from the following compounds, or its pharmaceutically acceptable salt; |
| Claim: | (1) pivaloyloxymethyl 7-[2-(2-L-alanylaminothiazol-4-yl )-2-methoxyiminoacetamide]-3-cephem-4-carboxylate hydrochloride (syn-isomer) |
| Claim: | (2) 1-ethoxycarbonyloxyethyl 7-[2-(2-L-alanylaminothiazol-4-yl )-2-methoxyiminoacetamide]-3-cephem-4-carboxylate hydrochloride (syn-isomer). |
| Claim: | 4. A cephalosporin compound according to claim 1 or its pharmaceutically acceptable salt which is a syn-isomer. |
| Claim: | 5. A cephalosporin compound according to claim 1, which is an L compound at the carbon atom marked with * in formula (I) of Claim 1, or its pharmaceutically acceptable salt. |
| Claim: | 6. An agent to be administered orally for the prophylaxis and treatment of bacterial infectious diseases, which comprises an effective amount of a cephalosporin compound of the formula (I) ##STR17## wherein R.sup.1 is hydrogen atom or lower alkyl, and R.sup.2 is 1-alkanoyloxyalkyl or 1-alkoxycarbonyloxyalkyl except 1-cyclohexyloxycarbonyloxyethyl, or its pharmaceutically acceptable salt as an active ingredient and a pharmaceutically acceptable excipient. |
| Claim: | 7. An agent to be administered orally for the prophylaxis and treatment of bacterial infectious diseases according to claim 6, which contains a pharmaceutically acceptable organic acid. |
| Claim: | 8. An agent to be administered orally for the prophylaxis and treatment of bacterial infectious diseases according to claim 7, wherein the organic acid is an organic carboxylic acid. |
| Claim: | 9. An agent to be administered orally for the prophylaxis and treatment of bacterial infectious diseases according to claim 8, wherein the organic carboxylic acid is at least one member selected from the group consisting of maleic acid, fumaric acid, tartaric acid, citric acid, succinic acid, malic acid, oxalic acid, mandelic acid, malonic acid and benzoic acid. |
| Claim: | 10. An agent to be administered orally for the prophylaxis and treatment of bacterial infectious diseases according to claim 7, wherein the organic acid comprises from 0.01 to 20 moles based on one mole of the compound of formula (I) or its acid addition salt. |
| Current U.S. Class: | 514/202; 540/222 |
| Current International Class: | C07D50122; A61K 31545 |
| Patent References Cited: | 4477447 October 1984 Ueda et al. |
| Primary Examiner: | Rizzo, Nicholas |
| Attorney, Agent or Firm: | Leydig, Voit & Mayer, Ltd. |
| رقم الانضمام: | edspgr.05389625 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |